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Introduction: The average age of the adult CF population is constantly increasing
and might imply a rise in number of malignancy cases in the adult CF population.
The previous studies on cancer incidence in CF adults emphasize a higher risk
of gastrointestinal (GI) cancer and to a lower extent other forms of cancer and
malignancies.
The aim of the study was to survey the number of cancer cases as well as other
malignancies in nontransplanted adults at the Stockholm CF center.
Results: The retrospective case analysis performed in 136 CF adult patients reveals
4 cases of GI cancer within the last decades. Two patients (at diagnosis 39 and
65 years old, respectively) have had high differentiated adenocarcinoma of the colon,
which was surgically removed. One of these patients was later lung transplanted and
up to now is doing well. The other one died but not due to cancer. The third patient
(age 44) had a cholangiocarcinoma and underwent radical surgery. Nevertheless
she died 7 months later due further progress of the tumour. The last patient (age
49 years old) has a suspect GIST (gastrointestinal stromal tumor). Its histological
veriﬁcation is in progress. One case of acute lymphatic leukemia was also observed.
This patient (age 27) is doing well after allogenic stem cell transplantation.
Conclusions: The data from the Stockholms CF center demonstrates an increased
cancer risk in the CF adult population in concert with the data from others. Since
the previous studies are from 1990s it would be of interest to disclose whether the
cancer incidence is increasing further due to the aging of the CF population. Time
for GI cancer screening program?
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Introduction and Aim: A yearly oral glucose tolerance test (OGTT) is advised to
diagnose CF-related diabetes (CFRD), from the age of 10 yrs and up. This test does
not reﬂect a real-life situation, is disliked by patients and not fully adhered to. The
aim of this study is to test the acceptance and results of a real-life glucose tolerance
test (RLGTT) and compare positive outcomes with the OGTT, from Jan 2010 to
Dec 2011.
Materials and Methods: For the yearly check up 33 children with CF of 10−17 yrs,
not already diagnosed with CFRD, were admitted. The carbohydrates of the meal
are registered according to the Dutch Food Composition Table 2006. The RLGTT
consists of a 4 hour fasting period followed by eating a minimum of 1.25 g
carbohydrates per kg bodyweight in a regular meal, with a maximum of 1.75 g/kg
or 75 g carbohydrates. A glucose sample is taken before and 2 hours after the meal.
A 2 hour glucose of >9mmol/L after 1.50–1.75 g/kg or >8mmol/L after 1.25–
1.50 g/kg is considered abnormal. Stricter cut-off values in comparison to OGTT
were set, because of the use of a meal instead of glucose.
Results: We did 47 tests in 33 patients. All patients easily accepted the test in this
design. An impaired fasting glycemia was found 2 times. In 7/47 tests (7/33 patients)
results were abnormal with a mean postprandial glucose of 11.0mmol/L (8.2 to
11.1mmol/L). In 6 patients an OGTT pointed out CFRD. They all started with
insulin once a day.
Conclusion: The RLGTT is a good predictor of CFRD, is easily accepted and
implemented in regular care. An abnormal RLGTT should be followed by intensive
monitoring of blood glucose.
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Objectives: CF-related diabetes (CFRD) is related to worsening pulmonary function
and increased mortality and its prevalence is signiﬁcantly high beyond the ﬁrst
decade of life. Current guidelines recommend annual OGTT as screening method
of CFRD for all CF patients 10 years. We evaluated glucose abnormalities among
patients 10 years regularly attending the CF Regional Centre of Naples.
Methods: From 2004 to 2010 67 patients 10 years (30 F) without CFRD were
screened for glucose abnormalities by fasting 2 h–1.75g/kg OGTT and classiﬁed
as NGT, IGT, INDET, CFRD according to current guidelines [1]. The inclusion
criteria were: pancreatic insufﬁciency, no acute pulmonary exacerbation and no
current steroid therapy. Mean age at the time of OGTT was 80.4 months (range
30–118), median age 83 months. We identiﬁed 18 NGT (26.8%), 4 INDET (6%),
11 IGT (16.4%), 4 CFRD (6%). 30 patients (44.7%) resulted with glucose levels
140mg/dl in the middle of OGTT.
Conclusions: More CF patients 10 years had glucose abnormalities than previous
reports. Our data suggest that also patients 10 years, have to be early screened for
CFRD. Larger prospective studies need to deﬁne the prognostic role of INDET and
IGT status, as well as to assess the prognostic role of abnormal glucose tolerance
(AGT − glucose level 140mg/dl in the middle of OGTT) in CF patients.
Reference(s)
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Introduction: UKCF Trust guidelines recommend all adult CF patients should
be screened annually for CFRD by oral glucose tolerance test (OGTT). This is
time consuming, inconvenient and disliked by some patients. We have previously
shown that using a combination of HbA1c, random glucose (RBG), annual FEV1
decline and annual weight loss to screen for CFRD may be an effective alternative
approach. To validate this in the wider CF population we performed the current
study to determine the most accurate criteria for predicting patients with a positive
OGTT requiring treatment.
Method: Prospective study of consecutive adult CF patients (not known to have
CFRD) attending an annual review assessment between March 2009 and December
2011. All patients had an OGTT. In parallel they had: HbA1c, RBG, and calculation
of annual %predicted FEV1 and weight decline.
Results: Data for 323 patients (mean±SD age = 31±10, 42% female, 76% pancre-
atic insufﬁcient) were collected. Mean±SD RBG = 5.40±1.6; HbA1c = 5.4±0.6;
annual %predicted FEV1 change −0.6%±2.7; annual %weight change +1%±3.
OGTT at 120min 7.8–11.0mmol/l, n = 43; at 120min >11, n = 17. By systematic
approach the optimal criteria for predicting a positive OGTT was: HbA1c 5.8%
(n = 171) and/or RBG >11mmol/l (n = 6). This provided a test accuracy of
94.1% sensitivity and 49.3% speciﬁcity. The one patient missed by these criteria is
clinically well and not currently requiring insulin.
Conclusion: This large study conﬁrms the validity of performing an OGTT selec-
tively. The use of two biochemical markers − HbA1c5.8% and RBG >11mmol/l −
provides an excellent test accuracy for CFRD screening, reducing the need for an
OGTT by nearly 50%.
